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Gitelman syndrome

David Steflik MD

Overview

Gitelman syndrome, also known as familial hypokalemia-hypomagnesemia, is an autosomal
recessive renal tubular salt-wasting disorder characterized by hypokalemic metabolic alkalosis
with hypomagnesemia and hypocalciuria.

Epidemiology

Gitelman is the most common renal tubular disorder among Caucasians, with a prevalence of 1
in 40000. It is transmitted as an autosomal recessive trait, with the prevalence of heterozygotes
at approximately 1% in the Caucasian population.1

Pathophysiology

In the majority of cases, Gitelman syndrome is caused by mutations in the SLC12A3 gene,
which encodes the renal thiazide-sensitive sodium-chloride co-transporter that is present in the
distal convoluted tubule.2 In comparison, the related Bartter syndrome is primarily a defect of
transporters in the thick ascending Loop of Henle, mainly the Na-K-2Cl cotransporter.

It may be useful to consider Gitelman a defect of the transporter where thiazide diuretics work,
and Bartter a defect where loop diuretics work. In a quick physiology refresher, thiazide
diuretics inhibit the sodium-chloride co-transporter in the early distal tubule. Loop diuretics
inhibit the sodium-2 chloride-potassium co-transporter in the thick ascending loop of Henle.

Clinical Presentation

In contrast to Bartter syndrome, which is usually diagnosed in infancy or early childhood (before
the age of 5) because of failure to thrive, Gitelman usually does not affect growth and typically
presents in late childhood to adulthood. It commonly presents with cramps of the arms and
legs, fatigue, ranging from mild to severe, seizures, polyuria and nocturia, chondrocalcinosis,
growth retardation if presents younger, and hypertension later in life.3 Prolonged Qtc and
arrhythmias with resultant palpitations and/or syncope has been estimated to occur in half of
affected patients.4

Differential diagnosis

There are a limited number of conditions that present with metabolic alkalosis and hypokalemia.
Prolonged vomiting (hyperemesis) and diuretic use can both present with metabolic alkalosis
and hypokalemia. Hyperemesis can be differentiated from Gitelman syndrome by characteristic
physical exam findings along with a urine chloride concentration <25 meq/L in vomiting. Urine
chloride concentration is high in Gitelman syndrome, often >40 meq/L. Sjogren syndrome can
also cause electrolyte abnormalities resembling Gitelman syndrome. Another cause is
administration of nephrotoxic agents such as cisplatin. Less common causes of metabolic
alkalosis and hypokalemia include undiagnosed cystic fibrosis and infants given chloride
deficient liquid formula.3

Diagnostic evaluation

Due to the relative rarity of Gitelman syndrome, it rarely is considered in the initial differential of
weakness, paresthesias, or seizures. However, it must be considered if serum electrolytes

show a metabolic alkalosis and hypokalemia, with corresponding low magnesium.

Further

workup should then include a spot urine calcium to creatinine ratio (Ca/Cr). A low ratio for age,
or normal calcium concentrations in the urine is expected in Gitelman syndrome. A high ratio of
calcium to creatinine, or a high 24 hour urine collection, supports the diagnosis of Bartter
syndrome. The expected calcium excretion greatly varies with age, so appropriate lab cut-offs
should be used to assess for hypercalciuria.5

EKG to assess for prolonged Qtc and risk of ventricular arrhythmias should be performed. In a
study of 21 patients with Gitelman syndrome, 11 had prolonged Qtc and therefore were at high
risk for ventricular arrhythmias.4

Genetic testing is not routinely performed, but mutations in the SLC12A3 gene correlate with
mutations in the thiazide sensitive Na-Cl cotransporter.6 The National Center for Biotechnology
Information will have up to date information regarding labs offering this genetic testing.

Treatment

Treatment of Gitelman consists of correcting the electrolyte disturbances which improves the
quality of life in these patients by decreasing fatigue, cramping, and risk of cardiac arrythmias.
The first mainstay of therapy is magnesium and potassium supplementation, with magnesium
supplementation being necessary to augment potassium normalization.

However, serum

magnesium normalization is difficult to obtain because high doses of magnesium cause
diarrhea.7 One group recommends magnesium chloride orally at doses of 3mmol Mg/m2/24hrs
or 4-5 mg/kg/24hours.2 The dose should be divided into 3-4 doses throughout the day to help
prevent diarrhea and adjusted according to serum magnesium levels.

Similar to patients

receiving steroids for adrenal insufficiency, the magnesium supplementation may have to be
increased during periods of illness, especially those with a component of vomiting and diarrhea.

The second mainstay of therapy is with a potassium sparing, direct aldosterone antagonist such
as Spironolactone. Spironolactone has been shown to be more effective than amiloride in
correcting the hypokalemia.8 Unlike Bartter, the defect in Gitelman syndrome does not increase
renal prostaglandin E2 production so NSAIDS are of no benefit in treatment.9
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